此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2018226722) TYROSINE KINASE INHIBITORS REGENERATE NON-CANCEROUS TISSUE AFTER CANCER THERAPY
国际局存档的最新著录项目数据    提交意见

公布号: WO/2018/226722 国际申请号: PCT/US2018/036102
公布日: 13.12.2018 国际申请日: 05.06.2018
国际专利分类:
A61K 31/4164 (2006.01) ,A61K 31/4196 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4196
1,2,4-Triazoles
申请人:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE [US/US]; 1800 Grant Street, 8th Floor Denver, Colorado 80203, US
发明人:
REYLAND, Mary; US
WIE, Sten; US
代理人:
TRAVER, Robert, D.; US
优先权数据:
62/515,45105.06.2017US
标题 (EN) TYROSINE KINASE INHIBITORS REGENERATE NON-CANCEROUS TISSUE AFTER CANCER THERAPY
(FR) INHIBITEURS DE TYROSINE KINASE RÉGÉNÉRANT UN TISSU NON CANCÉREUX APRÈS UNE THÉRAPIE ANTICANCÉREUSE
摘要:
(EN) Methods for inducing the regeneration of non-cancerous tissues in a cancer patient undergoing radiotherapy and/or chemotherapy using continuous administration of tyrosine kinase inhibitors for at least 90 days following a cancer treatment in the patient.
(FR) L'invention concerne des procédés d'induction de la régénération de tissus non cancéreux chez un patient cancéreux soumis à une radiothérapie et/ou une chimiothérapie au moyen de l'administration continue d'inhibiteurs de tyrosine kinase pendant au moins 90 jours après un traitement anticancéreux chez le patient.
front page image
指定国: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
非洲地区知识产权组织 (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
欧亚专利局 (AM, AZ, BY, KG, KZ, RU, TJ, TM)
欧洲专利局 (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
非洲知识产权组织 (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
公布语言: 英语 (EN)
申请语言: 英语 (EN)